Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS

Current Report · Items 5.03, 9.01 · 8-K

Kura Oncology, Inc.

KURANASDAQEQUITYCurrent

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.…

Filed Jan 29, 2026Accepted Jan 29, 2026, 5:25 PM ESTCIK 1422143Accession 0001193125-26-029705
Share

Company context

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Current securities

Recent company filings

  1. Other EventsSep 9, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 8, 2026
  3. 144 filingAug 21, 2026
  4. 4 filingAug 17, 2026
  5. SCHEDULE 13G/A - filed by MONTANOVA CAPITAL, LLC regarding Kura Oncology, Inc.Aug 14, 2026

Disclosure sections

Items 5.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date. The following is a summary of the material changes made to the Company’s amended and restated bylaws in effect prior to the adoption of the A&R Bylaws by the A&R Bylaws and is qualified in its entirety by reference to the full text of the A&R Bylaws, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference. Bylaw § Bylaw Change 1 Cause the A&R Bylaws to identify the registered office and agent by referencing the Company’s certificate of incorporation, as amended from time to time (the “Certificate of Incorporation”). ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 5(a) Revise who has authority to postpone, reschedule or cancel a meeting of stockholders. Require that stockholders who wish to nominate directors for election to the Board must be stockholders of record at the time of the annual meeting in addition to at the time they give notice of their proposed nomination. Clarify how a stockholder may make nominations for the Board and submit other business to come before an annual meeting of stockholders. 5(b)(i) Clarify the background information that must be provided regarding proponents of nominees to the Board and about the nominees themselves. Limit the maximum number of nominees to the Board that a stockholder may submit to be equal to the number of directors to be elected at the applicable meeting. Prohibit the nomination of substitute or alternate nominees to the Board without timely notice in accordance with the A&R Bylaws. 5(b)(ii) Require advance disclosure of resolutions or amendments to the A&R Bylaws that are the subject of a proposal to be brought before an annual meeting of stockholders. 5(b)(iii) Increase the period of time that an annual meeting date can be moved with respect to the anniversary of the previous year’s meeting date before an alternative window is applied for purpose of determining timely notice of stockholder proposals. As amended, the alternative window applies if the annual meeting date is advanced by more than 30 days prior to or delayed by more than 70 days (previously 30 days) after the anniversary of the preceding year’s annual meeting. Bylaw § Bylaw Change 5(b)(iv) Require additional information regarding proponents of stockholder proposals and director nominees and require such proponents to make certain representations and certifications related to the proposals or nominees, the proponents intended proxy solicitations, the cost of solicitation and the proponent’s compliance with applicable laws. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 5(c) Clarify the procedures for a proponent of stockholder proposals and director nominees to update the representations and certifications described in Section 5(b)(iv) above. 5(d) Clarify the procedures to be followed in the event the number of directors to be elected to the Board at an annual meeting is increased and there is no public announcement about such increase. 5(e) Clarify the provisions that require each proposed nominee to the Board to complete a written questionnaire and make certain representations and certifications about their candidacy, voting commitments, compensation for service and compliance with the Company’s corporate governance and other policies. 5(f) Provide explicit procedures regarding the validity or invalidity of proposals to nominate persons to the Board and the effects of failure by a proponent to follow such procedures. Require the stockholder (or its qualified representative) proposing a nominee to the Board or any other stockholder business to be present at the meeting of stockholders in order to nominate or present the business. Incorporate the universal proxy rules in Rule 14a-19 under the Securities Exchange Act of 1934, as amended. 6(a)-(b) Add clarity regarding who can postpone, reschedule or cancel special meetings of stockholders, and clarify how the Board can call a special meeting of stockholders, including its determination of the time and place of a special meeting. 6(c)-(d) Conform the advance notice procedures for stockholder proposals at a special meeting to the advance notice procedures for stockholder proposals at an annual meeting (as set forth in Section 5, discussed above). 7 Revise the provisions governing notice of meetings to conform to the current provisions in Section 222 of the General Corporation Law of the State of Delaware (“DGCL”). 8 • the holders of a majority of the outstanding shares entitled to vote; to • the holders of a majority of the outstanding shares entitled to vote; to • the holders of a majority of voting power of the outstanding shares entitled to vote. • the holders of a majority of voting power of the outstanding shares entitled to vote. Bylaw § Bylaw Change ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── • a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter; to • a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter; to • a majority of votes cast on such matter, voting affirmatively or negatively (excluding abstentions and broker non-votes). • a majority of votes cast on such matter, voting affirmatively or negatively (excluding abstentions and broker non-votes). 9 • approval by the chairman of the meeting or by the vote of a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting; to • approval by the chairman of the meeting or by the vote of a majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting; to • approval by the chairperson of the meeting or by the stockholders by the affirmative vote of a majority of the votes cast, voting affirmatively or negatively (excluding abstentions and broker non-votes). • approval by the chairperson of the meeting or by the stockholders by the affirmative vote of a majority of the votes cast, voting affirmatively or negatively (excluding abstentions and broker non-votes). Obviate the need for the Company to provide a new notice for an adjourned meeting if the means of remote communication are announced at the meeting at which adjournment takes place or is displayed on the website used for purposes of remote stockholder participation at the adjourned meeting. 10 Require the stockholder soliciting proxies use a proxy card color other than the “white proxy” that is reserved for the Company. 12 Modify the required preparation procedures, content and availability of the list of stockholders entitled to vote at a meeting in connection with the current provisions of the DGCL. 18 Omit the description of the Board classes and director terms from the A&R Bylaws and refer to the Certificate of Incorporation. 21 Cause the A&R Bylaws to refer to the Certificate of Incorporation for determining the procedures related to removal of a director. 25(a) Provide the Board additional flexibility in determining when to hold an adjourned special meeting. 26 • the date such consents are filed with the minutes of proceedings of the Board or committee; to • the date such consents are filed with the minutes of proceedings of the Board or committee; to • the date such consents are completed. • the date such consents are completed. Bylaw § Bylaw Change ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 28(d) • a majority of the authorized number of members of any such committee; to • a majority of the authorized number of members of any such committee; to • a majority of the members of the committee then serving unless the committee consists of one or two members, in which event one member shall constitute quorum of such committee. • a majority of the members of the committee then serving unless the committee consists of one or two members, in which event one member shall constitute quorum of such committee. 34 Modify the threshold required for the Board to remove an officer to make it consistent with the general threshold for Board actions described in Section 25(b). 40(a) Add procedures for the Board to fix the record date for determining the stockholders entitled to notice of any meeting of stockholders and, separately, the record date for determining the stockholders entitled to vote at such meeting. 42 Clarify the Board’s authority over the issuance, transfer and registration of shares of the Company, including the authority to choose the transfer agent and registrar and to issue shares in uncertificated form. 47(a)-(b) Expand the Company’s mandatory obligation to indemnify its directors and officers, and its discretionary authority to indemnify employees and other agents, to the maximum extent allowed by applicable law. Clarify the circumstances in which the Company is obligated to indemnify its directors and officers for certain claims brought against the Company and initiated by such a director or officer. Limit the Company’s obligation to advance expenses to its directors and officers for certain claims brought against the Company and initiated by such a director or officer unless such claims were authorized by the Board or were initiated to enforce rights to indemnification or advancement of expenses as provided for in Section 47(d) of the A&R Bylaws. 47(c) Subject to the limitations in Section 47(a), expand the Company’s mandatory obligation to advance expenses to directors and officers of the Company to the maximum extent allowed by applicable law, and clarify the procedure by which a director or officer is determined to be entitled to such advancement of expenses. 48(a)-(b) Clarify how notice may be delivered to stockholders and directors. 48(g) Identify the procedures for waiver of notice for any meeting, whether the meeting is regular or special or for stockholders, the Board or a committee of the Board in one place. 49 Omit the specific threshold required for the Board to amend the A&R Bylaws so that the general threshold for Board actions described in Section 25(b) governs. Bylaw § Bylaw Change 51 Enhance the forum selection provisions in the A&R Bylaws, including providing that Delaware federal courts will be the backup forum to the Delaware state courts for certain actions, and add a forum selection bylaw for claims under the Securities Act of 1933, as amended. ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Filed exhibits (1)
EX-99.1 (by filename) d18498dex991.htm

EX-99.1 2 d18498dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AMENDED AND RESTATED BYLAWS OF KURA ONCOLOGY, INC. (A DELAWARE CORPORATION) A MENDED AND R ESTATED E FFECTIVE AS OF J ANUARY 28, 2026 ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation’s Board of Directors (the “Board of Directors”) from time to time, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require. ARTICLE II CORPORATE SEAL Section 3. Corporate Seal. The Board of Directors may adopt a corporate seal. Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.